United Therapeutics Corp (UTHR) Stock AnalysisUTHRUnited Therapeutics Corp

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

United Therapeutics Corp is currently priced at $515.46, which is close to the recent analyst price target of $516 from Morgan Stanley, indicating limited upside potential in the short term. The stock has a forward P/E of 19.19, suggesting it is fairly valued relative to its expected earnings growth. However, the company has shown strong revenue growth with a 1-year change of +27.33%, and the gross margin remains high at 87.30%, indicating solid profitability. The main risk is the RSI at 46.33, which suggests the stock is neither overbought nor oversold, indicating potential volatility ahead.

13 analysts cover UTHR: 2 rate it Buy, 6 Hold and 5 Sell. The average price target is 534.50.